Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons

Area of Science:

• Immunology
• Hepatology
• Infectious Diseases

Background:

• Liver disease is a major cause of death in HIV-infected individuals, even with treatment.
• Hepatitis C Virus (HCV) co-infection is common in HIV patients and leads to poorer outcomes, often necessitating liver transplantation (LT).
• Post-LT outcomes remain suboptimal for patients with HIV-HCV co-infection.

Purpose of the Study:

• To identify pre-transplant immunologic biomarkers that predict outcomes after liver transplantation in HIV-HCV co-infected individuals.
• To investigate the association between immune activation, microbial translocation, and Th1/Th2 skewing with graft loss, rejection, and recurrent HCV post-LT.

Main Methods:

• A cohort of 69 HIV-HCV co-infected patients undergoing LT was studied.
• Pre-transplant immunologic biomarkers (sCD14, IL-10) were measured.
• Cox-proportional hazards models were used to analyze predictors of post-LT outcomes, including graft loss, rejection, and recurrent HCV.

Main Results:

• Lower pre-LT sCD14 levels were associated with increased risk of graft loss (HR 0.10).
• Higher pre-LT IL-10 levels were linked to a greater risk of acute rejection (HR 2.10).
• No specific biomarkers predicted severe recurrent HCV post-LT.

Conclusions:

• Pre-transplant monocyte activation, indicated by sCD14 and IL-10 levels, may be mechanistically linked to graft health and rejection risk in HIV-HCV co-infected patients undergoing liver transplantation.
• These biomarkers could potentially aid in risk stratification and management strategies for this vulnerable patient population.